Nalu Medical

Name

Nalu Medical

Legal name

Nalu Medical, Inc.

Website

https://nalumed.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Implantable Neurostimulation Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Neurostimulation therapy
• Chronic pain management
• Implantable pulse generators
• Peripheral nerve stimulation
• Spinal cord stimulation

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Neurostimulation System Sales: Sale of the Nalu Neurostimulation System including micro-IPG implants, Therapy Discs, leads, and accessories to healthcare providers. Revenue generated from commercial operations in the U.S. market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Nalu Medical develops and commercializes the Nalu Neurostimulation System, a battery-free, miniaturized neurostimulation platform for treating chronic intractable neuropathic pain of peripheral nerve origin and intractable trunk/limb pain. The system includes an implanted micro-Implantable Pulse Generator (micro-IPG), an externally worn Therapy Disc that powers the implant wirelessly, and a smartphone-based remote control app, and is FDA 510(k)-cleared for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. Nalu also provides the cloud-based Patient Care Portal for patient engagement across the trial-to-post-implant continuum.

Product overview

Nalu Medical offers the Nalu Neurostimulation System, a unified multi-component platform for treating chronic neuropathic pain through both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). The system centers on the proprietary nPower microchip powering the battery-free micro-IPG (mIPG), the smallest commercially available implantable pulse generator at 27x smaller than competitors. The mIPG is complemented by the externally worn Therapy Disc (with TD2 as its latest generation offering 39% size reduction), controlled via smartphone app. The Dual 4 mIPG variant extends PNS capabilities with dual-lead support, while the Patient Care Portal provides cloud-based patient monitoring. All components are software-upgradeable without surgery.

Differentiator

Problem solved

Functional benefit

Products and services

• Nalu Neurostimulation System A multi-component, non-integrated neurostimulation system for treating chronic intractable neuropathic pain, FDA 510(k)-cleared for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). The system comprises a battery-free implanted micro-Implantable Pulse Generator (micro-IPG), a separate electrode array, and an externally worn Therapy Disc that powers the implant wirelessly, with smartphone-based patient control. Designed for interventional pain specialists and pain management physicians treating patients who have failed conventional medical management.
• Therapy Disc (TD2) An externally worn device housing the battery and control circuitry that wirelessly powers the implanted micro-IPG, controlled by the patient via a smartphone app. The next-generation TD2 offers a 39% smaller volume than the prior Therapy Disc and incorporates a 3-axis MEMS accelerometer for activity monitoring, providing physicians and patients objective functional improvement data.
• Nalu Patient Care Portal A cloud-based software platform that engages patients with their multidisciplinary care teams from the trial period through post-implantation, enabling progress tracking and personalized pain management treatment plans. Used by interventional pain practices such as Premier Pain Centers to support patient tracking and recovery monitoring.
• Dual 4 mIPG A variant of the Nalu micro-Implantable Pulse Generator with dual connectors designed to accommodate two 4-contact stimulation leads for peripheral nerve stimulation applications. Provides increased treatment flexibility for addressing multiple nerve targets, utilized by pain physicians such as Dr. Amitabh Gulati for PNS applications.

Quantifiable outcome

• 85-87% responder rate (≥50% pain reduction) at 24 months
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Boston ScientificcoreStrategic or Co-development Partner · 17 October 2025Boston Scientific announced definitive agreement to acquire Nalu Medical for approximately $533 million in upfront cash. Boston Scientific had been a strategic investor in Nalu since 2017. Transaction completed in late January 2026. Nalu's neurostimulation technology complements Boston Scientific's existing neuromodulation therapies including spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation.
• Nevro CorporationminorStrategic or Co-development Partner · 22 December 2021Nalu and Nevro reached settlement in patent infringement lawsuit brought by Nevro in February 2020. Settlement allows Nalu to maintain its current menu of therapy options.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nevro Corp: Nevro is a direct competitor in the SCS market with its HF10 high-frequency therapy, and previously filed patent infringement litigation against Nalu (settled 2021), underscoring direct overlap in product category and clinical positioning.
• Saluda Medical: Saluda Medical developed the Evoke closed-loop SCS system with objective measurement of neural responses, directly competing in the chronic pain SCS market with differentiated waveform technology.
• Curonix (formerly Stimwave): Curonix is a direct PNS competitor with miniaturized, wirelessly powered peripheral nerve stimulators, sharing Nalu's core architectural approach of battery-free miniaturized implants and external wearable power sources.

Broad incumbents

• Medtronic: Medtronic is a dominant incumbent in spinal cord stimulation with its Intellis and Vanta platforms, offering overlapping chronic pain neuromodulation therapies to interventional pain physicians and competing with Nalu for the same clinical indications.
• Abbott: Abbott (which acquired St. Jude Medical's neuromodulation business) offers the Proclaim XR SCS system and Infinity DBS, directly competing in the chronic pain and neuromodulation space served by Nalu.
• Boston Scientific: Boston Scientific, now Nalu's parent company, is a broad neuromodulation incumbent with WaveWriter Alpha SCS, Precision Spectra, and other neurostimulation offerings — directly overlapping Nalu's product category within a much larger portfolio.
• Biotronik: Biotronik offers ProMRI-compatible spinal cord stimulators and other neurostimulation devices, competing in the chronic pain market with a portfolio extending across cardiovascular and neuromodulation verticals.

Emerging players

• SPR Therapeutics: SPR Therapeutics focuses on peripheral nerve stimulation with temporary 60-day SPRINT systems, addressing the same chronic peripheral nerve pain indications as Nalu's permanent PNS platform with a different care delivery model.
• Axonics: Axonics develops sacral and tibial neuromodulation systems for incontinence and chronic pain, with miniaturized rechargeable IPG technology. Founded by Nalu's Chairman Raymond Cohen; sold to Boston Scientific for $3.7B in 2024 — adjacent neuromodulation category with shared investor lineage.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NaluMed
• Facebookfacebook.com/nalumedical
• LinkedInlinkedin.com/company/nalu-medical-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nalu Medical